These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24375910)

  • 21. Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia.
    Layton ME; Kern JC; Hartingh TJ; Shipe WD; Raheem I; Kandebo M; Hayes RP; Huszar S; Eddins D; Ma B; Fuerst J; Wollenberg GK; Li J; Fritzen J; McGaughey GB; Uslaner JM; Smith SM; Coleman PJ; Cox CD
    J Med Chem; 2023 Jan; 66(2):1157-1171. PubMed ID: 36624931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors.
    Bauer U; Giordanetto F; Bauer M; O'Mahony G; Johansson KE; Knecht W; Hartleib-Geschwindner J; Carlsson ET; Enroth C
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1944-8. PubMed ID: 22321214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting the success of fragment screening by X-ray crystallography.
    Davies DR; Begley DW; Hartley RC; Staker BL; Stewart LJ
    Methods Enzymol; 2011; 493():91-114. PubMed ID: 21371588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mass spectrometry for fragment screening.
    Chan DS; Whitehouse AJ; Coyne AG; Abell C
    Essays Biochem; 2017 Nov; 61(5):465-473. PubMed ID: 28986384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of a novel 2-oxindole scaffold as a highly potent and brain-penetrant phosphodiesterase 10A inhibitor.
    Yoshikawa M; Kamisaki H; Kunitomo J; Oki H; Kokubo H; Suzuki A; Ikemoto T; Nakashima K; Kamiguchi N; Harada A; Kimura H; Taniguchi T
    Bioorg Med Chem; 2015 Nov; 23(22):7138-49. PubMed ID: 26494583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of a pyrazolo[1,5-a]pyrimidine derivative (MT-3014) as a highly selective PDE10A inhibitor via core structure transformation from the stilbene moiety.
    Koizumi Y; Tanaka Y; Matsumura T; Kadoh Y; Miyoshi H; Hongu M; Takedomi K; Kotera J; Sasaki T; Taniguchi H; Watanabe Y; Takakuwa M; Kojima K; Baba N; Nakamura I; Kawanishi E
    Bioorg Med Chem; 2019 Aug; 27(15):3440-3450. PubMed ID: 31235264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitors.
    Drinkwater N; Vu H; Lovell KM; Criscione KR; Collins BM; Prisinzano TE; Poulsen SA; McLeish MJ; Grunewald GL; Martin JL
    Biochem J; 2010 Oct; 431(1):51-61. PubMed ID: 20642456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery.
    Silvestre HL; Blundell TL; Abell C; Ciulli A
    Proc Natl Acad Sci U S A; 2013 Aug; 110(32):12984-9. PubMed ID: 23872845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cross-linking of protein crystals as an aid in the generation of binary protein-ligand crystal complexes, exemplified by the human PDE10a-papaverine structure.
    Andersen OA; Schönfeld DL; Toogood-Johnson I; Felicetti B; Albrecht C; Fryatt T; Whittaker M; Hallett D; Barker J
    Acta Crystallogr D Biol Crystallogr; 2009 Aug; 65(Pt 8):872-4. PubMed ID: 19622871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. N-Methylanilide and N-methylbenzamide derivatives as phosphodiesterase 10A (PDE10A) inhibitors.
    Kilburn JP; Kehler J; Langgård M; Erichsen MN; Leth-Petersen S; Larsen M; Christoffersen CT; Nielsen J
    Bioorg Med Chem; 2013 Oct; 21(19):6053-62. PubMed ID: 23978358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of novel PDE10 inhibitors by a robust homogeneous screening assay.
    Li QY; Xu MK; Liu G; Christoffersen CT; Wang MW
    Acta Pharmacol Sin; 2013 Aug; 34(8):1116-20. PubMed ID: 23603978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3).
    Hu E; Kunz RK; Rumfelt S; Andrews KL; Li C; Hitchcock SA; Lindstrom M; Treanor J
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6938-42. PubMed ID: 23044369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility.
    Rzasa RM; Frohn MJ; Andrews KL; Chmait S; Chen N; Clarine JG; Davis C; Eastwood HA; Horne DB; Hu E; Jones AD; Kaller MR; Kunz RK; Miller S; Monenschein H; Nguyen T; Pickrell AJ; Porter A; Reichelt A; Zhao X; Treanor JJS; Allen JR
    Bioorg Med Chem; 2014 Dec; 22(23):6570-6585. PubMed ID: 25456383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A three-stage biophysical screening cascade for fragment-based drug discovery.
    Mashalidis EH; Śledź P; Lang S; Abell C
    Nat Protoc; 2013 Nov; 8(11):2309-24. PubMed ID: 24157549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Six Biophysical Screening Methods Miss a Large Proportion of Crystallographically Discovered Fragment Hits: A Case Study.
    Schiebel J; Radeva N; Krimmer SG; Wang X; Stieler M; Ehrmann FR; Fu K; Metz A; Huschmann FU; Weiss MS; Mueller U; Heine A; Klebe G
    ACS Chem Biol; 2016 Jun; 11(6):1693-701. PubMed ID: 27028906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of natural product inhibitors of phosphodiesterase 10A as novel therapeutic drug for schizophrenia using a multistep virtual screening.
    Al-Nema M; Gaurav A; Akowuah G
    Comput Biol Chem; 2018 Dec; 77():52-63. PubMed ID: 30240986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape.
    Chappie T; Humphrey J; Menniti F; Schmidt C
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):458-67. PubMed ID: 19562642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and synthesis of novel benzimidazole derivatives as phosphodiesterase 10A inhibitors with reduced CYP1A2 inhibition.
    Hamaguchi W; Masuda N; Isomura M; Miyamoto S; Kikuchi S; Amano Y; Honbou K; Mihara T; Watanabe T
    Bioorg Med Chem; 2013 Dec; 21(24):7612-23. PubMed ID: 24238902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein X-ray Crystallography and Drug Discovery.
    Maveyraud L; Mourey L
    Molecules; 2020 Feb; 25(5):. PubMed ID: 32106588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.